Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
BioLife Solutions Inc is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS) are listed on the NASDAQ and all prices are listed in US Dollars. BioLife Solutions employs 193 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$40.93|
|52-week range||$27.42 - $60.67|
|50-day moving average||$48.56|
|200-day moving average||$41.47|
|Wall St. target price||$62.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.11|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||6.64%|
|1 month (2021-09-17)||-13.81%|
|3 months (2021-07-16)||-7.75%|
|6 months (2021-04-16)||19.78%|
|1 year (2020-10-16)||45.30%|
|2 years (2019-10-17)||145.53%|
|3 years (2018-10-17)||208.67%|
|5 years (2016-10-17)||2,365.66%|
Valuing BioLife Solutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLife Solutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioLife Solutions's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 337x. In other words, BioLife Solutions shares trade at around 337x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
BioLife Solutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 200.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLife Solutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioLife Solutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.3 million.
The EBITDA is a measure of a BioLife Solutions's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$74.1 million|
|Gross profit TTM||$27.9 million|
|Return on assets TTM||-1%|
|Return on equity TTM||1.25%|
|Market capitalisation||$1.6 billion|
TTM: trailing 12 months
There are currently 2.1 million BioLife Solutions shares held short by investors – that's known as BioLife Solutions's "short interest". This figure is 17% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting BioLife Solutions shares can be evaluated.
BioLife Solutions's "short interest ratio" (SIR) is the quantity of BioLife Solutions shares currently shorted divided by the average quantity of BioLife Solutions shares traded daily (recently around 851525.81967213). BioLife Solutions's SIR currently stands at 2.44. In other words for every 100,000 BioLife Solutions shares traded daily on the market, roughly 2440 shares are currently held short.
However BioLife Solutions's short interest can also be evaluated against the total number of BioLife Solutions shares, or, against the total number of tradable BioLife Solutions shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioLife Solutions's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 BioLife Solutions shares in existence, roughly 50 shares are currently held short) or 0.0715% of the tradable shares (for every 100,000 tradable BioLife Solutions shares, roughly 72 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioLife Solutions.
Find out more about how you can short BioLife Solutions stock.
We're not expecting BioLife Solutions to pay a dividend over the next 12 months.
BioLife Solutions's shares were split on a 1:14 basis on 28 January 2014. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLife Solutions shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for BioLife Solutions shares which in turn could have impacted BioLife Solutions's share price.
Over the last 12 months, BioLife Solutions's shares have ranged in value from as little as $27.42 up to $60.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLife Solutions's is 1.5534. This would suggest that BioLife Solutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.